Literature DB >> 3735250

Comparison of nifedipine and diltiazem with salbutamol for prevention of preterm delivery in the ovariectomized, oestrogen-treated late pregnant rat.

M H Abel, M Hollingsworth.   

Abstract

The ovariectomized, oestrogen-treated, late pregnant rat has been used to compare the ability of two calcium antagonists, diltiazem and nifedipine, with an agonist at beta-adrenoceptors, salbutamol, to prevent the development of uterine contractions, prolong gestation and maintain fetal survival in utero. Preterm delivery of the fetuses was not prevented in the animals infused with salbutamol (2 micrograms/kg/min), occurring at the same time, 30-40 h after ovariectomy, as in the saline-infused rats. The overall integral of uterine contractions was significantly reduced in the salbutamol-treated compared with the saline-treated animals due to decreased contractions after abortion. Both diltiazem (100 micrograms/kg/min) and nifedipine (3.1 and 6.2 micrograms/kg/min) produced significant inhibition of uterine contractions and in contrast to salbutamol prolonged gestation and improved fetal survival in utero as assessed at post mortem on Day 21. However, maternal survival was low (57%) with the higher dose of nifedipine, possibly reflecting the relaxant effect of this compound on vascular smooth muscle with consequent underperfusion of vital organs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3735250     DOI: 10.1530/jrf.0.0770559

Source DB:  PubMed          Journal:  J Reprod Fertil        ISSN: 0022-4251


  3 in total

1.  Tolerance to cromakalim in the rat uterus in vivo.

Authors:  S J Downing; M Miller; M Hollingsworth
Journal:  Br J Pharmacol       Date:  1989-03       Impact factor: 8.739

2.  Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects.

Authors:  S J Downing; D Edwards; M Hollingsworth
Journal:  Br J Pharmacol       Date:  1987-08       Impact factor: 8.739

3.  Nifedipine kinetics in the rat and relationship between its serum concentrations and uterine and cardiovascular effects.

Authors:  S J Downing; M Hollingsworth
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.